Analysts expect Amarin Corporation PLC (NASDAQ:AMRN) to post ($0.05) earnings per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Amarin Corporation PLC’s earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.06). Amarin Corporation PLC posted earnings of ($0.10) per share during the same quarter last year, which suggests a positive year over year growth rate of 50%. The business is scheduled to issue its next quarterly earnings results on Thursday, November 2nd.

On average, analysts expect that Amarin Corporation PLC will report full year earnings of ($0.21) per share for the current year, with EPS estimates ranging from ($0.23) to ($0.18). For the next fiscal year, analysts expect that the business will post earnings of $0.01 per share, with EPS estimates ranging from ($0.11) to $0.24. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Amarin Corporation PLC.

Amarin Corporation PLC (NASDAQ:AMRN) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. The company had revenue of $44.95 million for the quarter, compared to the consensus estimate of $40.35 million. During the same quarter in the previous year, the firm earned ($0.07) earnings per share. The company’s revenue for the quarter was up 37.0% compared to the same quarter last year.

A number of analysts recently issued reports on AMRN shares. Jefferies Group LLC restated a “buy” rating and issued a $5.00 price target on shares of Amarin Corporation PLC in a research report on Monday, June 12th. Zacks Investment Research downgraded Amarin Corporation PLC from a “buy” rating to a “hold” rating in a research report on Monday, August 7th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Amarin Corporation PLC in a research report on Wednesday. BidaskClub upgraded Amarin Corporation PLC from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 6th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $10.00 price target on shares of Amarin Corporation PLC in a research report on Monday, June 26th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $7.35.

Shares of Amarin Corporation PLC (NASDAQ:AMRN) traded up 1.87% during midday trading on Friday, reaching $3.26. 2,881,730 shares of the company’s stock traded hands. Amarin Corporation PLC has a one year low of $2.56 and a one year high of $4.47. The stock’s 50-day moving average price is $3.87 and its 200 day moving average price is $3.32. The firm’s market capitalization is $882.78 million.

In related news, General Counsel Joseph T. Kennedy sold 307,911 shares of Amarin Corporation PLC stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $4.00, for a total value of $1,231,644.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 3.72% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the stock. OxFORD Asset Management LLP increased its stake in Amarin Corporation PLC by 114.2% in the second quarter. OxFORD Asset Management LLP now owns 135,773 shares of the biopharmaceutical company’s stock valued at $547,000 after buying an additional 72,390 shares during the last quarter. GSA Capital Partners LLP raised its position in Amarin Corporation PLC by 135.4% in the second quarter. GSA Capital Partners LLP now owns 342,800 shares of the biopharmaceutical company’s stock valued at $1,381,000 after buying an additional 197,200 shares during the period. Wells Fargo & Company MN raised its position in Amarin Corporation PLC by 15.2% in the second quarter. Wells Fargo & Company MN now owns 37,801 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 5,000 shares during the period. JPMorgan Chase & Co. raised its position in Amarin Corporation PLC by 681.5% in the second quarter. JPMorgan Chase & Co. now owns 278,134 shares of the biopharmaceutical company’s stock valued at $1,121,000 after buying an additional 242,544 shares during the period. Finally, Airain ltd raised its position in Amarin Corporation PLC by 382.9% in the second quarter. Airain ltd now owns 87,122 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 69,081 shares during the period. Hedge funds and other institutional investors own 37.57% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.watchlistnews.com/amarin-corporation-plc-amrn-expected-to-post-earnings-of-0-05-per-share/1479064.html.

About Amarin Corporation PLC

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Get a free copy of the Zacks research report on Amarin Corporation PLC (AMRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amarin Corporation PLC (NASDAQ:AMRN)

Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.